Intelligent Product Solutions Selected for New York Product Design Award for Its Work on the EON Laser
HAUPPAUGE, N.Y., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Product Solutions (IPS) today announced that it received a New York Product Design award, for its product design work on the EON Laser, a FDA-cleared, touch-free, and pain-free fat reduction device by Dominion Aesthetic Technologies. A global product design and development firm, Intelligent Product Solutions is a subsidiary of Forward Industries (NASDAQ: FORD).
The New York Product Design awards honor the efforts of talented product designers, design teams and manufacturers from all over the world. It recognizes the contributions they have made to daily living, with their practical and ingenious creations.
'At IPS, we're proud to receive this award for our innovative medical device design of this revolutionary product,' said Bob Wild, CEO of Intelligent Product Solutions. 'Working with Dominion Aesthetic Technologies, together we are redefining the future of aesthetic medicine, leveraging our expertise in product design.'
The EON Laser introduces revolutionary technology in subcutaneous fat reduction, offering patients the industry's first touch-free and painless treatment option, delivering safer outcomes and eliminating recovery time. Utilizing laser energy, the EON Laser locally raises the temperature of subcutaneous fat, triggering lipolysis (the breakdown and metabolization of adipose tissue) while simultaneously cooling the skin, offering patients a pain-free alternative with unprecedented results. The scientifically proven EON Laser has received multiple FDA clearances and can be found at esthetic surgery centers and med-spas across the United States, offering patients a non-invasive alternative to liposuction and other surgical interventions.
'It's such a wonderful surprise to learn that EON has be recognized for its beautiful design,' said Janet Campbell, founder and Chairman of the Board, Dominion Aesthetic Technologies. 'It couldn't have been possible without the support of Intelligent Product Solutions. We are excited about the future of EON delivering the first of its kind non-invasive robotic fat reduction treatments. EON is dedicated to providing incredible patient outcomes with the safest fat reducing treatment available.'
About Intelligent Product Solutions
Intelligent Product Solutions (IPS), a subsidiary of Forward Industries (NASDAQ: FORD), is an award-winning global product design and development company with headquarters in New York. IPS offers a full range of expert product design and engineering services, with an expertise in medtech and wearable technology solutions. Its clients are among the leading brands in consumer electronics and medical devices, including Neuvotion, Google, Verizon, Zebra Technologies and Steinway. To learn more about IPS, visit https://intelligentproduct.solutions or contact info@ips-yes.com. Visit IPS on social media:https://www.linkedin.com/company/intelligent-product-solutions/
For more media information, contact:Lisa Hendrickson, LCH Communications for IPSLisa@lchcommunications.com516-643-1642
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/658ffae2-c750-4b47-adef-8c928e2c65fcSign in to access your portfolio
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
2 hours ago
- Business Upturn
Upsize LLC Opens New Male Enhancement Clinic in Dallas, Offering Revolutionary Non-Surgical Procedures
DALLAS, July 24, 2025 (GLOBE NEWSWIRE) — Upsize Clinic, a leading provider of non-surgical male enhancement treatments, announces the opening of its newest clinic location in Dallas at 5232 Forest Lane, Suite 170. The clinic, led by board-certified physician Dr. Brad Sellers, offers the company's proprietary Upsize™ and Firm-X™ procedures, providing men in the Dallas-Fort Worth metroplex access to clinically proven, minimally invasive male enhancement procedures. The new Dallas location represents Upsize's continued national expansion, following the company's recent milestone of surpassing 1,500 successful procedures across its network of 20 affiliated physicians nationwide. The clinic specializes in two groundbreaking treatments: the Upsize™ procedure utilizing hyaluronic acid dermal fillers for girth enhancement, and the Firm-X™ treatment employing neuromodulator injections for improved function and appearance. 'Dallas men now have access to safe, effective enhancement options that deliver immediate results without the risks and downtime associated with surgical procedures,' said Dr. Brad Sellers, Medical Director of Upsize Dallas. 'These innovative treatments represent a significant advancement in male aesthetic medicine, offering natural-looking results that boost confidence and improve quality of life.' About Dr. Brad Sellers Dr. Sellers brings over two decades of medical expertise to his practice, having served as Medical Director and Associate Medical Director at several prominent Dallas-area Emergency Departments and Level 1 and Level 2 Trauma Centers. His extensive background in emergency medicine, combined with his Certified Physician Executive credentials from the American Association of Physician Leaders, ensures the highest standards of patient safety and care. Recently completing specialized training in male enhancement procedures through Upsize LLC, as well as neurotoxin and dermal filler certification from the National Laser Institute, Dr. Sellers has expanded his practice to focus on intimate wellness and aesthetic treatments for men. His commitment to excellence and patient-centered approach makes him uniquely qualified to deliver these innovative procedures. The Upsize™ Procedure: Non-Surgical Girth Enhancement The flagship Upsize™ procedure uses FDA-approved hyaluronic acid dermal fillers (used off-label) administered via micro-cannula to achieve natural girth enlargement and improved symmetry. Key benefits include: Immediate Results : Patients see enhancement immediately following the 30-minute in-office procedure : Patients see enhancement immediately following the 30-minute in-office procedure Minimal Downtime : Most men return to normal activities within days : Most men return to normal activities within days Reversible Option : Results can be adjusted or reversed if desired : Results can be adjusted or reversed if desired Natural Feel : Maintains natural texture and sensation : Maintains natural texture and sensation Long-Lasting: Results typically last an average of 24 months Firm-X™: Revolutionary Neuromodulator Treatment The innovative Firm-X™ treatment utilizes neurotoxin injections to enhance male sexual health and appearance. This procedure works by relaxing smooth muscles in corpus cavernosum vasculature, leading to: Enhanced blood flow and circulation Reduced retraction for a fuller appearance Improvements in erectile dysfunction The treatment involves strategic placement of 100 units of neuromodulator through four injection points, with the entire procedure completed in under 30 minutes. Meeting Growing Demand for Male Enhancement The opening of Upsize Dallas addresses increasing demand for physician administered male aesthetic treatments in North Texas. As men become more comfortable seeking enhancement options, the need for safe, effective alternatives to risky surgeries and unregulated products has grown significantly. 'Men seeking enhancement deserve access to clinically proven treatments performed by qualified medical doctors,' Dr. Sellers noted. 'Our procedures offer a discreet, professional solution that prioritizes both results and safety.' Comprehensive Patient Care The Dallas clinic provides confidential consultations where patients can discuss their options and determine the most appropriate treatment plan. Both procedures are performed in a discrete, medical-grade facility with strict adherence to safety protocols. Patients receive lifetime follow-up care at no additional charge, ensuring ongoing support and satisfaction. About Upsize LLC Headquartered in Roseville, California, Upsize LLC specializes in minimally invasive male enhancement treatments. The company's proprietary procedures have earned recognition for their safety profile, immediate results, and high patient satisfaction rates. With locations across California, Texas, Florida, New York, New Jersey, Ohio, Arizona, Nebraska, and international expansion into Panama and Canada, Upsize continues to lead innovation in male aesthetic medicine. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash


Business Upturn
2 hours ago
- Business Upturn
Deadline Alert: Biohaven Ltd. (BHVN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES, July 24, 2025 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP reminds investors of the upcoming September 12, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Biohaven Ltd. ('Biohaven' or the 'Company') (NYSE: BHVN) securities between March 24, 2023 and May 14, 2025, inclusive (the 'Class Period'). IF YOU SUFFERED A LOSS ON YOUR BIOHAVEN INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? On July 17, 2023, Biohaven disclosed that the FDA had rejected the New Drug Application ('NDA') for its spinocerebellar ataxia ('SCA') treatment, troriluzole, having refused to even review the application after the Phase 3 SCA Trial had failed to meet its primary endpoint. On this news, Biohaven's stock price fell $5.38, or 22.6%, to close at $18.42 per share on July 27, 2023, thereby injuring investors. Then, on March 3, 2025, Biohaven released its fourth quarter and full year 2024 financial results, disclosing that recent data from a late-stage study of its BHV-7000 treatment for bipolar mania 'did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure[.]' On this news, Biohaven's stock price fell $5.12, or 13.8%, to close at $32.06 per share on March 3, 2025. Then, on April 25, 2025, news reports emerged that, according to the European Medicines Agency ('EMA'), Biohaven had withdrawn its Marketing Authorization Application ('MAA') for troriluzole in late March 2025. On this news, Biohaven's stock price fell $3.56, or 15.2%, to close at $19.84 per share on April 25, 2025. Then, on May 14, 2025, Biohaven announced that 'the Division of Neurology 1 within FDA's Office of Neuroscience informed the Company that they are extending the [Prescription Drug User Fee Act ('PDUFA')] date for the troriluzole [NDA] for the treatment of [SCA] by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA,' and that '[t]he Division also informed Biohaven that it is currently planning to hold an advisory committee meeting to discuss the application, but no date has been scheduled.' On this news, Biohaven's stock price fell $3.84, or 19.5%, to close at $15.82 per share on May 15, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) troriluzole's regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven's business and financial condition; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Biohaven securities during the Class Period, you may move the Court no later than September 12, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP,1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: [email protected] Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook.

Associated Press
2 hours ago
- Associated Press
CDx Diagnostics Receives FDA Breakthrough Device Designation for Its WATS3D Test System for Esophageal Cancer
Novel AI-powered laboratory test for diagnosis of Barrett's esophagus, with or without dysplasia SUFFERN, NEW YORK / ACCESS Newswire / July 24, 2025 / CDx Diagnostics announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for its proprietary WATS3D diagnostic system, a 'first-of-a-kind' AI-powered digital pathology system using wide area transepithelial sampling for the diagnosis of Barrett's esophagus and early neoplastic alterations in patients at risk for disease progression. 'The Breakthrough Device Designation recognizes what the volume of clinical data has shown: the WATS3D Test improves the ability to detect dysplasia in Barrett's esophagus, offering patients and physicians an improved method of detection of patients at risk of development of esophageal cancer,' said Robert Odze, MD, a leading gastrointestinal pathologist. To meet the requirements for FDA Breakthrough Device Designation, CDx Diagnostics submitted technical and clinical evidence from large multi-center studies showing that the WATS3D Test is 'more effective' than the Seattle biopsy protocol for the diagnosis of Barrett's esophagus, dysplasia and esophageal cancer. 'With data from greater than 23,000 patients, the WATS3D Test continues to demonstrate its potential to detect early-stage neoplastic disease that might be missed with conventional biopsies,' said Karen Hoffman, MD, Director of R&D at CDx Diagnostics. 'This designation recognizes the science behind our platform and supports our ongoing efforts to improve early detection of patients at risk.' The WATS3D Test System leverages proprietary artificial intelligence (AI) enabled algorithm for analysis of high-resolution digital pathology using novel 3-dimensional images from specimens collected using the WATS3D brush to identify precancerous and cancerous cells and assess the risk of progression to cancer. The WATS3D System was developed by CDx Diagnostics and is performed in the company's CLIA-certified, CAP accredited, New York state licensed clinical laboratory in Suffern, NY. For more information, visit or contact us at [email protected]. About CDx Diagnostics CDx Diagnostics' mission is to Empower Physicians with Innovative Technology to Prevent Esophageal Cancer, One Patient at a Time. CDx Diagnostics is changing the landscape of cancer prevention and diagnosis through innovative AI-driven digital pathology solutions developed and performed in the company's CLIA-certified, CAP accredited clinical laboratory in Suffern, New York. The company's first advanced diagnostic test- the WATS3D Test system powered by the WATS3D Esophageal AI Algorithm - has FDA Breakthrough Device Designation for the diagnosis of Barrett's esophagus (BE), with and without dysplasia. About the WATS3D Test System The WATS3D Test system is an AI-powered digital pathology test system that helps prevent the progression of neoplasia via more effective identification of Barrett's esophagus (BE), low-grade dysplasia (LGD), high-grade dysplasia (HGD), and esophageal adenocarcinoma (EAC). Developed and performed by CDx Diagnostics, the WATS3D Test leverages artificial intelligence (AI) enabled analysis using the WATS3D Esophageal AI Algorithm and 3D digital imaging of samples collected using a WATS3D brush to identify precancerous and cancerous cells and evaluate the risk of progression to cancer. The WATS3D Test has been used to analyze over 400,000 patient samples to identify those requiring earlier intervention, reduce time to treatment, and improve patient outcomes. Contact Information William Standwill Marketing [email protected] 845-777-7000 SOURCE: CDx Diagnostics press release